Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 26605 | 19.2049 |
09:34 ET | 63184 | 18.93 |
09:36 ET | 21585 | 18.99 |
09:38 ET | 28152 | 19.04 |
09:39 ET | 42254 | 18.95 |
09:41 ET | 19654 | 18.9201 |
09:43 ET | 66728 | 18.9 |
09:45 ET | 15499 | 18.896 |
09:48 ET | 34555 | 18.88 |
09:50 ET | 16541 | 18.875 |
09:52 ET | 35388 | 18.825 |
09:54 ET | 4572 | 18.88 |
09:56 ET | 12098 | 18.92 |
09:57 ET | 16036 | 18.81 |
09:59 ET | 14000 | 18.89 |
10:01 ET | 11595 | 18.81 |
10:03 ET | 3920 | 18.84 |
10:06 ET | 15234 | 18.9 |
10:08 ET | 12563 | 18.91 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 14.4B | -82.3x | --- |
Vaxcyte Inc | 15.2B | -24.5x | --- |
Insmed Inc | 12.5B | -13.6x | --- |
Ascendis Pharma A/S | 8.9B | -15.1x | --- |
Revolution Medicines Inc | 7.7B | -12.6x | --- |
Viking Therapeutics Inc | 7.2B | -70.3x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.4B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 735.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.93 |
EPS | $-0.23 |
Book Value | $0.11 |
P/E Ratio | -82.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.